
Colorectal Cancer
Latest News
Latest Videos

CME Content
More News

Results of a large expanded access program, presented at the 2015 World Congress on GI Cancer, confirmed the efficiency and safety of regorafenib (Stivarga) in previously treated patients with mCRC.

Guy Van Hazel, MD, Medical Oncologist, Mount Hospital and School of Medicine University of Western Australia, discusses the effects of selective internal radiation therapy (SIRT) and bevacizumab on extrahepatic colorectal cancer (CRC) metastases.

Luis Alberto Diaz, Jr, MD, associate professor of Oncology, Johns Hopkins University, discusses PD-1 blockade in mismatch repair deficiency in colorectal cancer (CRC).

The survival benefit observed with regorafenib over placebo in Asian patients who had been previously treated for mCRC in the international phase III CORRECT trial was confirmed by the phase III CONCUR trial.







Metastatic CRC with Marwan G. Fakih, MD and Tanios Bekaii-Saab, MD









Metastatic CRC with Marwan G. Fakih, MD and Tanios Bekaii-Saab, MD

Reactivation of the tumor suppressor gene adenomatous polyposis coli (Apc) reverted colorectal cancer cells back to normal intestinal tissue in mice, according to a recent preclinical study.

Low expression of the genes ERCC1 and TS was associated with substantial improvements in overall survival following front-line treatment with an oxaliplatin-based chemotherapy regimen for patient with metastatic colorectal cancer.

Treatment with panitumumab improved overall survival compared with best supportive care in patients with chemorefractory KRAS wild-type metastatic colorectal cancer.

Hand-foot skin reaction represents one of the most troublesome adverse events associated with the multikinase inhibitor regorafenib, yet most treating physicians are unfamiliar with management tactics for this debilitating side effect.

The combination of selective internal radiation therapy (SIRT) with first-line chemotherapy showed a 31% reduction in the risk of disease progression within the liver of patients with metastatic colorectal cancer (mCRC) compared with chemotherapy alone.








































